Biotech Values

[genisi]

SGEN SGN-CD33A AML trial clinical hold

hopefully it is target specific and not due to the new ADC platform

ADCs with payloads based on auristatins and maytansines are used in Adcetris and Kadcyla respectively, both with manageable, tolerated safety profile. This off-target tox could be the target or the new PBD dimer payloads. Me think it's the payload, so for now I would worry about SGN-CD70A (think SGN-CD123A and SGN-CD352A too), as it has a similar structure with identical payload as SGN-CD33A (a different antibody component of course).